news
FDA grants Fast Track Designation to Novavax COVID-19 vaccine candidate
The FDA has given Fast Track Designation to NVX-CoV2373, Novavax’s COVID-19 vaccine candidate, created using recombinant nanoparticle technology.
List view / Grid view
Vaccines
webinar
How to master raw material ID testing in 2021
11 November 2020 | By Thermo Fisher Scientific
In this on-demand webinar we explore the evolving role of handheld and portable instruments to drive quality improvements and manufacturing success in 2021.
news
Pfizer COVID-19 vaccine candidate over 90 percent effective, Phase III study shows
The COVID-19 vaccine candidate BNT162b2, made by Pfizer and BioNTech, has demonstrated over 90 percent efficacy in its first interim analysis during its Phase III trial.
news
CVnCoV COVID-19 vaccine safely elicits immune response in Phase I testing
The interim Phase I data suggests CVnCoV can safely induce a neutralising antibody response similar to that of convalescent COVID-19 patients with two 12μg vaccine doses.
whitepaper
Fact sheet: TOC monitoring efficiency quiz
Take our 10-question quiz to find out how efficient your Total Organic Carbon (TOC) monitoring programme is for your applications.
![Artist's depiction of an ultrapotent COVID-19 vaccine candidate in which 60 pieces of a coronavirus protein (red) decorate nanoparticles (blue and white). The vaccine candidate was designed using methods developed at the UW Medicine Institute for Protein Design. The molecular structure of the vaccine roughly mimics that of a virus, which may account for its enhanced ability to provoke an immune response [Credit: Ian Haydon/ UW Medicine Institute for Protein Design].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Nanoparticle-covid-19-vaccine-300x278.jpg)
![Artist's depiction of an ultrapotent COVID-19 vaccine candidate in which 60 pieces of a coronavirus protein (red) decorate nanoparticles (blue and white). The vaccine candidate was designed using methods developed at the UW Medicine Institute for Protein Design. The molecular structure of the vaccine roughly mimics that of a virus, which may account for its enhanced ability to provoke an immune response [Credit: Ian Haydon/ UW Medicine Institute for Protein Design].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Nanoparticle-covid-19-vaccine.jpg)
news
Highly potent nanoparticle COVID-19 vaccine designed using computer
Developers suggest that the potency, stability and manufacturability of the nanoparticle vaccine candidate could enable vaccination against COVID-19 on a global scale.
news
Takeda to supply Japan with Moderna’s COVID-19 vaccine
Takeda will import and distribute 50 million doses of the mRNA-1273 vaccine candidate under an agreement with Moderna and Government of Japan.
article
Scaling up production capacity when the world is waiting
As the race to develop a COVID-19 vaccine intensifies, nations are already ramping up production capacity on a scale never seen before – but what does this mean for manufacturers? Here, Rod Schregardus makes the case for advanced planning and scheduling techniques in new and existing facilities.
news
FDA approves first-in-human trial of COVID-19 vaccine candidate
The safety and immunogenicity of CORVax12, a novel DNA-encodable COVID-19 vaccine, will be evaluated in 36 healthy volunteers.
news
200 million doses of COVID-19 vaccine to be made available for COVAX
Sanofi and GSK have agreed to support the COVID-19 vaccine (COVAX) Facility with 200 million doses of their adjuvanted, recombinant protein-based COVID-19 vaccine.
news
News: Microbial solutions product portfolio updates
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.
news
Clinical trials to study AstraZeneca’s COVID-19 vaccine resume globally
Clinical trials for AZD1222, the AstraZeneca COVID-19 vaccine candidate, have resumed across the world after confirmation it is safe to do so.
video
On-demand webinar: What you need to know about USP <1085>
Watch the webinar that analyses the most important points introduced by the newest USP Chapter 1085 on endotoxin testing guideline and their impact.
news
UK to establish human challenge studies for COVID-19 vaccines
The UK government hopes to expedite the development of a COVID-19 vaccine by investing £33.6 million in the first phase of establishing human challenge trials.
news
J&J pauses COVID-19 vaccine clinical trial after participant illness
J&J has paused its Phase III trial for its COVID-19 vaccine candidate following an unexplained illness in a study participant.
